Merck Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates
Collaboration complements Merck’s internal expertise and in-house ADC approach Companies focused on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana’s proprietary Immunosy